ライフサイエンスコーパス: premenopausal

1 hormone-releasing hormone [LHRH] agonist if premenopausal).

2 rimary analysis included 1,450 women, mostly premenopausal.

3 53.3% had received chemotherapy and remained premenopausal.

4 trol), the median age was 46 years; 69% were premenopausal, 29% were postmenopausal, and 2% were unkn

5 4 years [range, 25-86 years]; P < .0001), be premenopausal (55 of 86 [64%] vs 349 of 845 [41%], P < .

6 Among premenopausal AA women, comparing variant allele carrier

7 SOFT patients who remained premenopausal after chemotherapy experienced absolute im

8 Methods In SOFT, women still premenopausal after surgery with or without chemotherapy

9 id (FA) storage and FA storage factors in 12 premenopausal and 11 postmenopausal women matched for ag

10 Overall, 4747 (89.8%) premenopausal and 12502 (95.1%) postmenopausal women wit

11 without breast cancer, with a total of 58146 premenopausal and 144600 postmenopausal women enrolled i

12 rotocol, a total of 51 serum samples from 26 premenopausal and 25 postmenopausal women were analyzed.

13 on the PARP; 39.3% (95% CI, 36.6%-42.0%) of premenopausal and 26.2% (95% CI, 24.4%-28.0%) of postmen

14 Of 147 patients, 68 (46%) were premenopausal and 79 (54%) were postmenopausal.

15 s the Nation (SWAN) followed 3,302 initially premenopausal and early perimenopausal women from 7 US s

16 lateral hippocampal connectivity relative to premenopausal and perimenopausal women.

17 linked to an increased incidence of TNBC in premenopausal and postmenopausal African American women.

18 s was inversely associated with risk of both premenopausal and postmenopausal breast cancer (per 1-un

19 e time of mammography, and more than half of premenopausal and postmenopausal breast cancers are expl

20 Gender (premenopausal and postmenopausal females), age (prepuber

21 In the IBIS-I randomised controlled trial, premenopausal and postmenopausal women 35-70 years of ag

22 was the most prevalent risk factor for both premenopausal and postmenopausal women and had the large

23 infection rates remains significant in both premenopausal and postmenopausal women when compared wit

24 Participants were premenopausal and postmenopausal women who had been diag

25 ase were not significantly different between premenopausal and postmenopausal women.

26 ence and recurrence of breast cancer between premenopausal and postmenopausal women.

27 th clinical breast cancer risk factors among premenopausal and postmenopausal women.

28 Forty-one (44%) of the 93 patients were premenopausal, and 52 (56%) were postmenopausal.

29 In all, 4,534 women were premenopausal, and 6,481 postmenopausal, at the time of

30 ce were used as models for adolescent, adult premenopausal, and elderly postmenopausal women, respect

31 Overall, men, premenopausal, and postmenopausal women composed 35.1%,

32 of 203 late-reproductive-age women who were premenopausal at baseline and reached natural menopause.

33 re identified from all participants who were premenopausal at baseline in 1991; over 1.13 million per

34 gen receptor-positive breast cancer who were premenopausal at diagnosis and who underwent chemotherap

35 cer appeared to be limited to women who were premenopausal at the time of a case [HR=1.07 (95% CI: 1.

36 we observed that women with TNBC had higher premenopausal body mass index and earlier age at first f

37 he inverse association between adult BMI and premenopausal breast cancer (for BMI >/=30 vs. BMI 20-22

38 intake was associated with a higher risk of premenopausal breast cancer (P for trend = 0.002).

39 ociated with an increased risk of developing premenopausal breast cancer (P for trend = 0.04) and for

40 e was also associated with a reduced risk of premenopausal breast cancer (RR: 0.57; 95% CI: 0.34, 0.9

41 in never-smokers (prostate 0.96, 0.93-0.99; premenopausal breast cancer 0.89, 0.85-0.94).

42 isk, both overall (prostate 0.98, 0.95-1.00; premenopausal breast cancer 0.89, 0.86-0.92) and in neve

43 were associated with an 85% reduced risk of premenopausal breast cancer [relative risk (RR), 0.15; 9

44 ons of folate status with risk of developing premenopausal breast cancer and ER-positive or PR-positi

45 e has been associated with a reduced risk of premenopausal breast cancer in non-Hispanic white women.

46 ern score had multivariable adjusted HRs for premenopausal breast cancer of 1.35 for adolescent diet

47 ole of adiponectin as a potential target for premenopausal breast cancer prevention and treatment.

48 The authors examined the association between premenopausal breast cancer risk and adult body size in

49 olism are hypothesized to be associated with premenopausal breast cancer risk but evidence is limited

50 he inverse association between adult BMI and premenopausal breast cancer risk may be partially due to

51 ass index (BMI) is inversely associated with premenopausal breast cancer risk, and childhood and adol

52 mated inverse associations with prostate and premenopausal breast cancer risk, both overall (prostate

53 The multivariable-adjusted relative risk of premenopausal breast cancer was 0.92 (95% confidence int

54 e, was inversely associated with the risk of premenopausal breast cancer, and the association was hig

55 tions between number of nevi and the risk of premenopausal breast cancer, BBD, and family history of

56 the wives' use was associated primarily with premenopausal breast cancer.

57 diets, is associated with increased risk of premenopausal breast cancer.

58 protective effect of soy food intake against premenopausal breast cancer.

59 es, and coffee may increase the incidence of premenopausal breast cancer.

60 common consequence of systemic treatment for premenopausal breast cancer.

61 We investigated COX-2 regulation in normal premenopausal breast tissue and its relationship to mali

62 ow baseline COX-2 expression is regulated in premenopausal breast tissue because COX-2 levels in norm

63 as associated with an increased incidence of premenopausal but not postmenopausal breast cancer.

64 Parity was inversely associated with premenopausal but not postmenopausal ovarian cancer.

65 In premenopausal but not postmenopausal patients with hormo

66 lites and reproductive hormones in a healthy premenopausal cohort and evaluated potential effect modi

67 KRAS variant, compared with 27 (13%) of 201 premenopausal controls (p=0.015).

68 intracardiac anti-fibrotic cytokines, while premenopausal diabetic female rats do not.

69 patients (32%; 95% CI, 25% to 39%) developed premenopausal E2 without menses.

70 ncreasing age in latent precancers of normal premenopausal endometrium.

71 bination AC and in which all patients except premenopausal estrogen receptor (ER)-negative patients r

72 ry is likely linked to the pubertal rise and premenopausal fall of estradiol levels and results in th

73 ascular disease occurs at lower incidence in premenopausal females compared with age-matched males.

74 Although premenopausal females have a lower risk for cardiovascul

75 for sex and up to 41% false discoveries when premenopausal females were not matched for oral contrace

76 prevalence of periodontal diseases among US premenopausal females.

77 rophy had higher BW (41.4% +/- 9.6) than the premenopausal group by 135% (P < .001) and the postmenop

78 ion] vs 17.4% +/- 2.2, P < .001) than in the premenopausal group, and patients with renal osteodystro

79 with younger age at blood collection, being premenopausal, having an older age at menopause, and nev

80 We examined the relationship between premenopausal hysterectomy and EOC in African-American w

81 3-2001), we investigated the associations of premenopausal hysterectomy and oophorectomy with breast

82 sent; among never users of estrogen-only HT, premenopausal hysterectomy was associated with a signifi

83 Premenopausal hysterectomy was inversely associated with

84 Although research indicates that premenopausal hysterectomy with bilateral oophorectomy d

85 Premenopausal hysterectomy, even without ovary removal,

86 similar across menses groups, compared with premenopausal monkeys, peri/postmenopausal monkeys had f

87 ncies to levels comparable to young and aged premenopausal monkeys.

88 cases were included, with an oversampling of premenopausal (n = 582) and estrogen receptor-negative (

89 ely provide a means to preserve fertility in premenopausal oncology patients.

90 n may result in premature ovarian failure in premenopausal oncology patients.

91 c anxiety symptoms among older women who are premenopausal or who consistently take postmenopausal HR

92 The associations were similar for both premenopausal (OR = 0.44, 95% CI:0.31-0.62, p = 9.91 x 1

93 measures and for women who are nonwhite, are premenopausal, or have comorbid conditions were lacking.

94 pared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy.

95 ared with no systemic treatment (control) in premenopausal patients with breast cancer over different

96 Premenopausal patients with early breast cancer on the S

97 resulted in a long-term survival benefit in premenopausal patients with estrogen receptor-positive p

98 Premenopausal patients with primary breast cancer (N = 5

99 For evaluation of premenopausal patients, adherence was 63% (overmanagemen

100 erse symptoms, of which some are specific to premenopausal patients.

101 generally occurred for physiologic cysts in premenopausal patients; undermanagement was observed for

102 corresponded to the upper half of the normal premenopausal reference range.

103 pausal or postmenopausal compared with being premenopausal remained significantly associated with a C

104 Women who had not undergone premenopausal reproductive surgery were the referent gro

105 cranial arterial stenosis when compared with premenopausal status in the univariate analysis (OR = 1.

106 Compared with premenopausal status, postmenopausal status is associate

107 Compared with no history of premenopausal surgery, bilateral oophorectomy and hyster

108 h is needed to expand evidence-based care in premenopausal survivors of breast cancer.

109 rrant adjuvant chemotherapy and who remained premenopausal, the addition of ovarian suppression impro

110 uring 1997-2007, the authors followed 22,120 premenopausal US Black Women's Health Study participants

111 weight loss maintenance among 4,558 healthy, premenopausal US women who had previously lost >5% of th

112 Premenopausal volunteers (n = 16) underwent imaging week

113 he lactating volunteers as compared with the premenopausal volunteers (P < .005).

114 ed with the group with HRT use (P < .01) and premenopausal volunteers (P < .01) and (b) in the lactat

115 al contraceptives (P = .28-0.82) and between premenopausal volunteers and postmenopausal volunteers w

116 erences in DTI parameters were found between premenopausal volunteers free of oral contraceptives and

117 In all premenopausal volunteers, the DTI parameters exhibited h

118 mone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who a

119 in their own clinical practice.A 36-year-old premenopausal woman had been diagnosed with stage III br

120 A 45-year-old premenopausal woman presented with multifocal cancer in

121 Case Report: We report a case of AH in a premenopausal woman presenting with headache.

122 in their own clinical practice.A 46-year-old premenopausal woman with a body mass index of 21 was fou

123 A 42-year-old premenopausal woman with osteogenesis imperfecta present

124 ies (children 9-13 y old, males >/=14 y old, premenopausal women >/=19 y old, and postmenopausal wome

125 Among 2027 premenopausal women (13.1%), biennial screeners had high

126 The association was restricted to premenopausal women (HR = 1.40, ptrend = 0.01), even aft

127 significantly lower risk of breast cancer in premenopausal women (IRR: 0.70; 95% CI: 0.52, 0.96; P fo

128 ER(+) cell frequencies, respectively, among premenopausal women (Ki67(hi)/p27(lo): OR = 5.08, 95% CI

129 included 98 previously sexually functioning, premenopausal women (mean [SD] age 37.1 [6] years) whose

130 st association with fat mass was observed in premenopausal women (n = 1192; P = .02).

131 Premenopausal women (n = 27) consumed a choline-sufficie

132 ciated with triple-negative breast cancer in premenopausal women (odds ratio 2.307, 95% CI 1.261-4.21

133 al/Val genotype was seen predominantly among premenopausal women (OR = 2.08; 95% CI = 1.20, 3.59).

134 sal women (OR, 0.6; 95% CI, 0.4-0.8) than in premenopausal women (OR, 0.8; 95% CI, 0.6-1.1).

135 ely associated with breast cancer risk among premenopausal women [OR = 10.1, 95% confidence interval

136 mammograms linked to 1283 breast cancers in premenopausal women according to week of menstrual cycle

137 fected men aged 40-49 years and HIV-infected premenopausal women aged >/=40 years.

138 actors was 52.7% (95% CI, 49.1%-56.3%) among premenopausal women and 54.7% (95% CI, 46.5%-54.7%) amon

139 the mean (SD) age was 46.3 (3.7) years among premenopausal women and 61.7 (7.2) years among the postm

140 intake and reproductive hormones in healthy premenopausal women and evaluated the potential effect m

141 age, was lower in postmenopausal compared to premenopausal women and in smokers compared to non-smoke

142 and earlier start and end to childbearing in premenopausal women and obesity in postmenopausal women

143 with the number of alleles of rs12325817 in premenopausal women and whether postmenopausal women (wi

144 cancer, and disproportionally affects young premenopausal women and women of African descent.

145 ll sample, but associations were found among premenopausal women and women who consistently took horm

146 in in breast cancer etiology, yet studies in premenopausal women are scarce.

147 es more favorable tumor characteristics when premenopausal women are screened annually vs biennially.

148 wever, data on its physiologic regulation in premenopausal women are sparse.

149 nd 1.6 (1.0, 2.5) (P = 0.03) for men, having premenopausal women as a reference.

150 ed by serum 25-hydroxyvitamin D (25-OHD), in premenopausal women at initiation of adjuvant chemothera

151 n (18)F-FDG uptake was seen predominantly in premenopausal women at mid menstrual cycle.

152 nostic effect on recurrence-free survival in premenopausal women at risk for breast cancer.

153 This mechanism results in premenopausal women being more susceptible to angiogenes

154 Unlike age-matched men, premenopausal women benefit from cardiovascular protecti

155 ated with a reduced risk of breast cancer in premenopausal women but an increased risk in postmenopau

156 ed follicular estradiol concentrations among premenopausal women but does not appear to affect ovulat

157 However, only a portion of premenopausal women developed such problems.

158 Premenopausal women diagnosed as having breast cancer fo

159 study were largely null, it is possible that premenopausal women exposed to passive smoke or carrying

160 risk factors or outcomes based on studies of premenopausal women followed through the menopause trans

161 A total of 259 healthy, premenopausal women from Western New York were followed

162 Premenopausal women had a greater risk of breast cancer

163 Premenopausal women had significantly higher BEC when co

164 gen metabolites and breast cancer risk among premenopausal women in a case-control study nested withi

165 e intake and breast cancer risk among 90,628 premenopausal women in the Nurses' Health Study II.

166 metric, lifestyle, and dietary factors among premenopausal women in the United States.

167 However, a significant subset of premenopausal women is protected from CDS.

168 ing the Mediterranean diet with lower LPO in premenopausal women is sparse.

169 This cross-sectional study of 494 premenopausal women is the first to account for cyclic v

170 ein intakes for optimizing bone health among premenopausal women is unclear.

171 examined the effect in healthy, overweight, premenopausal women of a diet and exercise weight-loss p

172 xcess risk was observed for breast cancer in premenopausal women or for thyroid cancer.

173 n for the primary prevention of fractures in premenopausal women or in men.

174 ologic (18)F-FDG uptake in normal ovaries of premenopausal women poses another limitation.

175 Postmenopausal women, or premenopausal women receiving a gonadotropin-releasing h

176 Premenopausal women receiving chemotherapy for BC sustai

177 Premenopausal women should be advised of the potential e

178 with screening of women ages 40-49 years (or premenopausal women starting at age 40 years) making a n

179 serial breast biopsy analysis in nonpregnant premenopausal women suggested relatively stable baseline

180 (pmol PtdCho-DHA/nmol PtdCho) was higher in premenopausal women than in men and postmenopausal women

181 prevalence of ID and IDA is often greater in premenopausal women than other population demographics.

182 east cancer recurrence overall, although for premenopausal women there was a significant inverse asso

183 duces expression of the PEMT gene and allows premenopausal women to make more of their needed choline

184 Premenopausal women undergoing chemotherapy for breast c

185 ne whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast c

186 Premenopausal women undergoing commonly used genotoxic (

187 effect on ovarian function and fertility in premenopausal women undergoing treatment for early-stage

188 a in preventing early ovarian dysfunction in premenopausal women undergoing treatment for EBC were se

189 Premenopausal women underwent serial BMD measurements be

190 ference in percent MD (PD) between post- and premenopausal women was apparent (-0.46 cm [95% CI: -0.5

191 Twelve healthy Caucasian premenopausal women were compared to a group of healthy

192 In all, 345 premenopausal women were enrolled: 171 on tamoxifen alon

193 Healthy premenopausal women were followed for </=2 menstrual cyc

194 Over an 8-y period (2001-2009), 12,044 premenopausal women were followed for a first diagnosis

195 From 1997 to 2009, 23,580 premenopausal women were followed for incident uterine l

196 A total of 60 healthy, overweight, premenopausal women were included in a 6-mo weight-loss

197 were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen

198 After 4 months of tamoxifen, premenopausal women who did not receive adjuvant chemoth

199 Premenopausal women who first gave birth before age 20 y

200 OR], 4.16; 95% CI, 1.29-13.45; P = .02), and premenopausal women who gave birth to their last child b

201 From December 2008 to August 2011, 58 premenopausal women who had undergone contrast material-

202 Conclusion: Premenopausal women who undergo regular screening may be

203 Cases were predominantly premenopausal women who were diagnosed with incident bre

204 We included premenopausal women who were diagnosed with invasive bre

205 ultures of voided midstream urine in healthy premenopausal women with acute uncomplicated cystitis ac

206 Forty premenopausal women with AN and 40 normal-weight women o

207 Premenopausal women with axillary node-negative, hormone

208 Fifty-five men and 85 premenopausal women with BMI 18-24 (lean) and 27-36 kg/m

209 Premenopausal women with breast cancer receiving adjuvan

210 Premenopausal women with breast cancer, and specifically

211 Thirty-four young premenopausal women with early-stage breast cancer who w

212 Ovarian preservation in premenopausal women with early-stage endometrial cancer

213 nt Ovarian Ablation (OA) in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Can

214 Among premenopausal women with either hormone receptor-positiv

215 Oophorectomy is commonly performed in premenopausal women with endometrial cancer who undergo

216 all genotyped individuals, eight (33%) of 24 premenopausal women with ER/PR-negative cancer had the K

217 Premenopausal women with estrogen and/or progesterone re

218 nvestigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breas

219 ntial antitumor activity in the treatment of premenopausal women with hormone receptor-positive metas

220 Premenopausal women with hormone receptor-positive, HER2

221 Between Nov 7, 2003, and April 7, 2011, 4717 premenopausal women with hormone-receptor positive breas

222 In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early

223 In premenopausal women with hormone-receptor-positive early

224 ualize endocrine therapy decision making for premenopausal women with human epidermal growth factor r

225 ns in 1996-1999 and 2007, we ascertained 310 premenopausal women with incident endometriosis and 615

226 r than previous studies and included 102,164 premenopausal women with intact uteri, no prior history

227 ent normal and breast cancer tissues from 96 premenopausal women with known clinical reproductive his

228 In this population of healthy premenopausal women with low exposure levels, cadmium, l

229 We randomly assigned 257 premenopausal women with operable hormone-receptor-negat

230 Between October 2003 and January 2008, 281 premenopausal women with stage I to III hormone receptor

231 This ratio was lower in premenopausal women with the rs12325817 polymorphism in

232 ith advanced-stage tumors, and the lowest in premenopausal women with triple-negative cancer.

233 hysterectomy specimens from normally cycling premenopausal women with uterine fibroids, who were not

234 (interquartile range, 21.8%; n = 230) among premenopausal women, 31.0% (interquartile range, 23.2%;

235 associated with the menstrual status (BEC in premenopausal women, 31.48 +/- 20.68 [standard deviation

236 Participants were 72 healthy premenopausal women, ages 19-52 years, with no current o

237 In this paper I propose that, in premenopausal women, an iron deficiency caused by menstr

238 elopment of triple-negative breast cancer in premenopausal women, and altered gene and miRNA expressi

239 ions were 140.7, 49.4, and 96.7 mg/L in men, premenopausal women, and postmenopausal women, respectiv

240 Power was low for premenopausal women, and the associations were not signi

241 Screening of women ages 40-49 years (or premenopausal women, as determined from patient history,

242 gical outcomes associated with ID and IDA in premenopausal women, as the prevalence of ID and IDA is

243 one-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxif

244 ifen has greater efficacy and can be used in premenopausal women, but raloxifene has fewer side-effec

245 ntaining beverages are widely consumed among premenopausal women, but their association with reproduc

246 For premenopausal women, higher intake of folate was associa

247 oductive hormones and oxidative stress among premenopausal women, however, has yet to be clearly eluc

248 al FA, and direct free FA (FFA) storage than premenopausal women, including two-fold greater meal FA

249 breast cancer risk were null, whereas among premenopausal women, nonsignificant positive association

250 Among regularly screened premenopausal women, obesity was not associated with inc

251 ibrosis is greater in postmenopausal than in premenopausal women, perhaps owing to protective effects

252 We randomly assigned 3066 premenopausal women, stratified according to prior recei

253 remenstrual syndrome (PMS) affects 15-20% of premenopausal women, substantially reducing quality of l

254 In premenopausal women, tamoxifen for 5 years reduces the r

255 Among premenopausal women, TCDD serum levels were associated w

256 Among premenopausal women, the association with OS was stronge

257 Among premenopausal women, the radicalPD difference per 10-yea

258 l dysphoric disorder, which affects 2%-5% of premenopausal women, was included in Appendix B of DSMIV

259 ic tachycardia syndrome (POTS) are primarily premenopausal women, which may be attributed to female s

260 strogen therapies, particularly tamoxifen in premenopausal women.

261 ared with breast cancers diagnosed in young, premenopausal women.

262 noteworthy associations were observed among premenopausal women.

263 y cycles and sporadic anovulation in healthy premenopausal women.

264 thdrawal and induced hypogonadism in healthy premenopausal women.

265 a cross-sectional study of fibroids in 1152 premenopausal women.

266 level of symptom burden was similar in older premenopausal women.

267 lead to progression of ER+ breast cancer in premenopausal women.

268 ely associated with breast cancer risk among premenopausal women.

269 lymorphism is responsible for this effect in premenopausal women.

270 luated patterns among regularly menstruating premenopausal women.

271 f anti-estrogen therapies to treat cancer in premenopausal women.

272 tor to disease severity in children, men, or premenopausal women.

273 nd patient prognosis, most prominently among premenopausal women.

274 r risk of second breast neoplastic events in premenopausal women.

275 t but are not worse than those seen in older premenopausal women.

276 term habituation in 16 obese and 16 nonobese premenopausal women.

277 us (LBSQ) fat were measured in 28 men and 53 premenopausal women.

278 sterol levels independent of estradiol among premenopausal women.

279 gher dietary requirement for choline than do premenopausal women.

280 and to correlate amenorrhea with outcomes in premenopausal women.

281 associated with lower LPO concentrations in premenopausal women.

282 ociation between fiber and cholesterol among premenopausal women.

283 e does not have an adverse effect on bone in premenopausal women.

284 lude ovulation, has not been well studied in premenopausal women.

285 cations; long-term effects; and nonwhite and premenopausal women.

286 ual syndrome (PMS) affects as many as 20% of premenopausal women.

287 n and those of the Native Mexican diet among premenopausal women.

288 e consistent among postmenopausal than among premenopausal women.

289 targeted biologic therapy, and treatment of premenopausal women.

290 .19 +/- 0.11 vs 0.30 +/- 0.12; P < .05) than premenopausal women.

291 improved menstrual cycle function in healthy premenopausal women.

292 EXT, alongside data from the cohort of older premenopausal women.

293 uppression or ablation should be included in premenopausal women.

294 xhibited a pattern of brain activity akin to premenopausal women.

295 eased risk of hepatic fibrosis compared with premenopausal women.

296 ne-related organ dysfunction was observed in premenopausal women: 80%, 43%, and 13% of women with 2,

297 n; 27.2%, 17.2%, and 10.6%, respectively, in premenopausal women; and 18.4%, 12.7%, and 10.5%, respec

298 s that endogenous hormones affect density in premenopausal women; in particular, it shows a positive

299 /dL) for early postmenopausal, compared with premenopausal, women were 2.1 (95% confidence interval:

300 ancer for women in their post-child-bearing, premenopausal years, when lactation is readily avoidable